Want to see HNGE full AI Analyst Report?
Hinge Health, Inc. Class A (HNGE) AI Stock Analysis
Top Page
Hinge Health, Inc. Class A
(NYSE:HNGE)
The score is driven primarily by strong financial momentum (high growth, high gross margins, low leverage, and surging cash generation) and a very positive earnings update with raised guidance and expanding operating income. Offsetting factors are a stretched valuation (high P/E, no dividend yield provided) and a technically extended setup (overbought signals), alongside ongoing questions about earnings quality given the prior period’s large net loss despite strong cash flow.
Hinge Health, Inc. Class A (HNGE) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $9.22B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.89M
- Price to Earnings (P/E)
- 84.9
- Beta (1Y)
- 1.68
- Revenue Growth
- 49.76%
- EPS Growth
- ―
- Country
- US
- Employees
- 1,437
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Hinge Health, Inc. Class A Business Overview & Revenue Model
Company Description
Established in 2012 and headquartered in San Francisco, California, Hinge Health, Inc. creates specialized healthcare software solutions for musculoskeletal and joint health. Their advanced platform is designed to comprehensively manage a spectrum of...
How the Company Makes Money
Public, company-specific details sufficient to describe Hinge Health, Inc. (HNGE) revenue model and key revenue streams are not available in the information provided here; therefore, this data point is null.
Hinge Health, Inc. Class A Earnings Call Summary
The call presents a strongly positive operational and financial story: high top-line growth (+53% Q2 revenue), substantial billings momentum (+52% LTM billings), marked margin and free cash flow expansion (operating margin +1,000 bps YoY; free cash flow 3x YoY), raised guidance, and concrete product/TAM expansion (Migraine traction and the $105M Cylinder acquisition to enter GI). Key risks are manageable near-term execution items — integrating Cylinder, some non-recurring margin tailwinds (tariff refund), reliance on continued yield improvements for upside, and heightened competitive noise. Overall, the positives (growth, profitability, cash generation, product traction, and clinical evidence) materially outweigh the near-term integration and concentration risks.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Hinge Health raised its outlook, guiding Q3 revenue to $223–225M (midpoint $224M, +45% YoY) and Q3 operating income to $61–63M (≈28% operating margin at the midpoint); for full-year 2026 it now expects revenue of $856–860M (midpoint $858M, +46% YoY) and operating income of $236–244M (≈28% operating margin at the midpoint, up from prior $217–227M / ~27%); management expects yield ≈4.45% for the year, ASP roughly flat, eligible lives tracking in line, diluted shares to finish 2026 at 85–87M, Cylinder Health to contribute roughly $7–8M of revenue for the remaining ~4 months of 2026, and the board approved a $300M share repurchase authorization.
Hinge Health, Inc. Class A Financial Statement Overview
Summary
Strong overall fundamentals: very rapid revenue growth and consistently high gross margins, low debt relative to equity, and sharply improving operating/free cash flow. The main drag is earnings quality/volatility—profitability deteriorated materially in 2025 despite strong cash flow, creating uncertainty around normalized margins.
Income Statement
36NegativeBalance Sheet
74PositiveCash Flow
78Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 720.06M | 587.86M | 390.40M | 292.73M |
| Gross Profit | 608.59M | 469.30M | 300.59M | 194.18M |
| EBITDA | 103.59M | -535.89M | -18.48M | -124.89M |
| Net Income | 109.07M | -528.26M | -11.93M | -108.14M |
Balance Sheet | ||||
| Total Assets | 827.40M | 744.76M | 673.26M | 622.53M |
| Cash, Cash Equivalents and Short-Term Investments | 389.39M | 363.86M | 466.57M | 423.36M |
| Total Debt | 5.88M | 8.04M | 11.07M | 15.73M |
| Total Liabilities | 483.07M | 366.23M | 256.56M | 195.25M |
| Stockholders Equity | 344.33M | 378.54M | 416.70M | 427.28M |
Cash Flow | ||||
| Free Cash Flow | 287.33M | 170.73M | 45.23M | -68.52M |
| Operating Cash Flow | 290.79M | 171.44M | 49.00M | -63.91M |
| Investing Cash Flow | -19.75M | -113.76M | 18.31M | 1.50M |
| Financing Cash Flow | -222.34M | -150.47M | -2.20M | -3.00M |
Hinge Health, Inc. Class A Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HNGE, the sentiment is Positive. The current price of 114.32 is above the 20-day moving average (MA) of 106.58, above the 50-day MA of 98.17, and above the 200-day MA of 67.06, indicating a bullish trend. The MACD of 5.21 indicates Negative momentum. The RSI at 67.50 is Neutral, neither overbought nor oversold. The STOCH value of 89.92 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HNGE.
Hinge Health, Inc. Class A Risk Analysis
Hinge Health, Inc. Class A disclosed 83 risk factors in its most recent earnings report. Hinge Health, Inc. Class A reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
2 New RisksHinge Health, Inc. Class A Peers Comparison
Overall Rating
- HNGE73Outperform
PRVA70Outperform
OMDA67Neutral
AMWL53Neutral
TDOC52Neutral
VSEE40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HNGE | 73Outperform | $9.22B | 84.89 | 30.25% | ― | 49.76% | ― |
| PRVA | 70Outperform | $2.74B | 95.51 | 0.01% | ― | 24.10% | 84.08% |
| OMDA | 67Neutral | $1.15B | 275.85 | 1.84% | ― | 47.63% | ― |
| AMWL | 53Neutral | $216.52M | -2.67 | -33.27% | ― | -19.00% | 40.98% |
| TDOC | 52Neutral | $1.55B | -9.89 | -11.63% | ― | -2.38% | 32.73% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| VSEE | 40Underperform | $1.43M | -0.05 | -400.87% | ― | -9.31% | 89.42% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HNGE | Hinge Health, Inc. Class A | 114.32 | 63.98 | 127.10% | |
| TDOC | Teladoc Inc. | 8.51 | 0.37 | 4.55% | |
| AMWL | American Well Corporation | 12.73 | 7.64 | 150.10% | |
| PRVA | Privia Health Group, Inc. | 21.48 | -3.28 | -13.25% | |
| VSEE | Vsee Health, Inc. | 1.78 | -77.42 | -97.75% | |
| OMDA | Omada Health, Inc. | 18.73 | -6.94 | -27.04% |
Hinge Health, Inc. Class A Corporate Events
Hinge Health Expands Corporate Footprint with Major SF Lease
PositiveOn August 18, 2026, Hinge Health, Inc. signed a long-term lease for about 119,278 rentable square feet of office space at 300 Mission Street in San Francisco, California, marking a significant physical expansion of its operations. The lease, which is...
Hinge Health Posts Record Q2 Results, Raises Outlook
PositiveHinge Health, Inc. is a San Francisco-based digital health company focused on scaling and automating the delivery of care using an AI-powered model, connected hardware and expert clinicians. The company specializes in musculoskeletal programs and is...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026